European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy, announced the success of a €20M Series B fundraising led by Relyens Innovation Santé / Turenne Capital, followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital.
